Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 147-154

  Remacha, Angel F ^e   Arrizabalaga, Beatriz ^a   Del Cañizo, Consuelo ^b   Sanz, Guillermo ^c   Villegas, Ana ^d  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e NONE

Author keywords

Chelation; Deferasirox; DFO; Iron; MDS; Overload

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTARABINE; DEFERASIROX; DEFEROXAMINE; ERYTHROPOIETIN; ETOPOSIDE; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYUREA; LENALIDOMIDE; THALIDOMIDE; THYMOCYTE ANTIBODY; VITAMIN B GROUP; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHELATION THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN CELL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BENZOIC ACIDS; CHELATION THERAPY; DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYELODYSPLASTIC SYNDROMES; TRIAZOLES;

EID: 74049120461     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0794-7     Document Type: Article

References (24)

1. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088.
2. Aul C, Gattermann N, Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358-367.
3. Aul C, Germing U, Gattermann N, Minning H (1998) Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 22:93-100.
4. Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81:104-130.
5. Modell B, Khan M, Darlison M (2000) Survival in betathalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355:2051-2052.
6. Greenberg PL (2006) Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 4:91-96.
7. Malcovati L, Della Porta MG, Cazzola M (2006) Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91:1588-1590.
8. Valent P, Horny HP, Bennett JM et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727-736.
9. Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31(Suppl 3):S2-S6.
10. Malcovati L, Porta MG, Pascutto C et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594-7603.
11. Ozment CP, Turi JL (2009) Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 1790:694-701.
12. Gattermann N (2008) Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 88:24-29.
13. Bennett JM (2008) Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83:858-861.
14. Jaeger M, Aul C, Sohngen D, Germing U, Schneider W (1992) Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes. Beitr Infusionsther 30:464-468.
15. Sanz G, Nomdedeu B, Such E et al (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. ASH Annual Meeting Abstracts 112:640.
16. Gattermann N (2007) Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 31(Suppl 3):S10-S15.
17. Mittelman M, Lugassy G, Merkel D et al (2008) Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr Med Assoc J 10:374-376.
18. Takatoku M, Uchiyama T, Okamoto S et al (2007) Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78:487-494.
19. Leitch HA, Goodman TA, Wong KK, Vickars LM, Galbraith PF, Leger CS (2006) Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. ASH Annual Meeting Abstracts 108:249.
20. Rose C, Brechignac S, Vassilief D et al (2007) Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. ASH Annual Meeting Abstracts 110:249.
21. Valent P, Krieger O, Stauder R et al (2008) Iron overload in myelodysplastic syndromes (MDS)-diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 38:143-149.
22. González FA, Arrizabalaga B, Villegas A et al (2005) Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes. Med Clin (Barc) 124:645-647.
23. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1:S4-S8.
24. Barton JC (2007) Optimal management strategies for chronic iron overload. Drugs 67:685-700.